Five Prime (FPRX)

Company Description

Five Prime is a leader in the discovery of innovative protein therapeutics.

We have developed a library of more than 5,700 human extracellular proteins, which we believe represent substantially all of the body’s medically important targets for protein therapeutics.

Building on this expertise in protein science, we have developed proprietary high-throughput protein screening technologies that we use to identify new targets for protein therapeutics in relatively short periods of time. As a result, we have built a pipeline of novel product candidates for cancer and inflammatory diseases.

Our drug discovery platform has also made us a sought-after discovery and development partner. To date we have generated over $262 million from collaborations with partners, including Bristol-Myers Squibb, GlaxoSmithKline and UCB Pharma.

Our strategy is to be opportunistic in our development programs. Pursuing clinical development of our product candidates both independently and in collaborations allows us to enhance the capital resources needed to strengthen our core technology and expand our product pipeline.

 

COMPANY ADDRESS
Two Corporate Drive
South San Francisco, CA 94080
United States

COMPANY PHONE
415-365-5600

COMPANY WEBSITE


Get BioInvest's perspective on Five Prime’s CEO

Latest Company News

Five Prime Therapeutics Inc. (FPRX) Moves Higher on Volume Spike for March 24 Equities.com - 4 hours ago Five Prime Therapeutics Inc. (FPRX) traded on unusually high volume on Mar. 24, as the stock gained 3.12% to close at $35.98. Analyst Activity – Cowen and Company Initiates Coverage On Five Prime ... - Market Exclusive Dimensional Fund Advisors LP Has $42147000 Position in Five Prime Therapeutics ... - The Cerbat Gem [...]
Fri, Mar 24, 2017 9:30:00 PM, Continue reading at the source
Analysts Near-Term outlook: Five Prime Therapeutics, Inc. (FPRX), Lions Gate ... The USA Commerce - 10 hours ago Shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) dropped -3.22% to $34.89. During the trading on 03/23/2017, Company's stock ranged from $36.14 to $34.71. [...]
Fri, Mar 24, 2017 3:45:00 PM, Continue reading at the source
Five Prime Therapeutics Inc. (FPRX) Plunges 5.53% on March 21 Equities.com - Mar 21, 2017 Five Prime Therapeutics Inc. (FPRX) had a rough trading day for Tuesday March 21 as shares tumbled 5.53%, or a loss of $-2.17 per share, to close at $37.04. Five Prime Therapeutics, Inc. (FPRX) held by 25 SEC 13F Filers - Post Analyst [...]
Tue, Mar 21, 2017 9:30:00 PM, Continue reading at the source
Five Prime Therapeutics Announces Executive Changes Yahoo Finance - Mar 20, 2017 SOUTH SAN FRANCISCO, Calif., March 20, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today ... Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Files An 8-K Other Events - Market Exclusive Stock Returns: Five Prime Therapeutics Inc (NASDAQ:FPRX) is Beating Intrexon ... - CML News [...]
Mon, Mar 20, 2017 8:03:00 PM, Continue reading at the source
Five Prime Therapeutics Becomes Oversold (FPRX) Nasdaq - Mar 17, 2017 In trading on Friday, shares of Five Prime Therapeutics, Inc (Symbol: FPRX) entered into oversold territory, hitting an RSI reading of 28.7, after changing hands as low as $38.80 per share. [...]
Fri, Mar 17, 2017 4:07:00 PM, Continue reading at the source
Five Prime Therapeutics posts 4Q loss Yahoo Finance - Feb 23, 2017 (AP) _ Five Prime Therapeutics Inc. (FPRX) on Thursday reported a fourth-quarter loss of $20.1 million, after reporting a profit in the same period a year earlier. Five Prime Therapeutics' (FPRX) CEO Rusty Williams on Q4 2016 Results ... - Seeking Alpha Five Prime Announces Fourth Quarter and Full Year 2016 Financial Results - GlobeNewswire (press release) [...]
Thu, Feb 23, 2017 10:52:00 PM, Continue reading at the source
Five Prime to Present Preclinical Research Data at 2017 AACR Annual Meeting GlobeNewswire (press release) - Feb 8, 2017 SOUTH SAN FRANCISCO, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today ... [...]
Wed, Feb 08, 2017 9:00:00 PM, Continue reading at the source
Why Five Prime Therapeutics Rocketed 109% Higher in October Motley Fool - Nov 14, 2015 So what: On Oct. 15, Bristol-Myers Squibb and Five Prime Therapeutics announced a collaboration deal to develop Five Prime Therapeutics colony stimulating factor 1 receptor (CSF1R) antibody program for use alongside Bristol-Myers PD-1 inhibitor Opdivo ... [...]
Sat, Nov 14, 2015 2:40:00 PM, Continue reading at the source
Five Prime Therapeutics: Ridiculously Undervalued Seeking Alpha - Oct 16, 2015 I think this could be the case with Five Prime Therapeutics (NASDAQ:FPRX) after a recent $1.74 billion dollar deal with Bristol-Myers Squibb (NYSE:BMY). BMS expands Five Prime CSF1R deal, pledging billions for potential combinations - BioWorld Online BMS, Five Prime Sign $1.74B Deal to Develop Opdivo-CSF1R Immuno-Oncology ... - Genetic Engineering & Biotechnology News (press release) [...]
Fri, Oct 16, 2015 6:32:00 PM, Continue reading at the source
Five Prime Therapeutics and Bristol-Myers Squibb Co. Deepen Their Ties Motley Fool - Oct 15, 2015 What: Shares of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company, rose by more than 65% today on tremendous volume after the company announced a new worldwide license and collaboration agreement with Bristol-Myers ... Five Prime Therapeutics (FPRX) Enters Collaboration with Bristol-Myers Squibb ... - StreetInsider.com Five Prime, Bristol Shake Hands Again in New $350M Cancer Pact - Xconomy [...]
Thu, Oct 15, 2015 9:22:00 PM, Continue reading at the source